Brief: Mannkind Launches Inhale-3 Study To Address The Most Important Unmet Need Today In Adults Living With Type 1 Diabetes
22/06/2023 11:52
June 22 (Reuters) - MannKind Corp MNKD.O :
* MANNKIND LAUNCHES INHALE-3 STUDY TO ADDRESS THE MOST
IMPORTANT
UNMET NEED TODAY IN ADULTS LIVING WITH TYPE 1 DIABETES (T1D)
Source text for Eikon: ID:nGNX1mpXdd
Further company coverage: MNKD.O
((reuters.briefs@thomsonreuters.com;))
Recent news on MannKind
See all newsBrief: MannKind Enters Data-Rich Development Period With Completion Of Randomization In Phase 1B Inflo-1 Study And Enrollment Of First Patient In Phase 2 Inflo-2 Trial For Nintedanib Dpi In Patients With Ipf
U.S. STOCKS ON THE MOVE-Dell, Gap, Costco
MannKind rises after FDA approves inhaled insulin for children
US FDA approves MannKind's inhaled insulin for children (updated)
US FDA approves MannKind's inhaled insulin for children